Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes

This multicenter, randomized, crossover trial compared hybrid closed loop therapy (artificial pancreas) with sensor augmented pump therapy in very young children (1–7 years) with type 1 diabetes. The study involved 74 participants across Austria, Germany, Luxembourg, and the United Kingdom. Results showed that closed loop therapy significantly improved glycemic control, with 8.7 percentage points more time spent in the target glucose range (70–180 mg/dL) compared to sensor augmented pump therapy (P<0.001). The closed loop system also reduced hyperglycemia and glycated hemoglobin levels without increasing hypoglycemia. The findings support the efficacy and safety of closed loop systems in this age group.

This multicenter, randomized, crossover trial compared hybrid closed loop therapy (artificial pancreas) with sensor augmented pump therapy in very young children (1–7 years) with type 1 diabetes. The study involved 74 participants across Austria, Germany, Luxembourg, and the United Kingdom. Results showed that closed loop therapy significantly improved glycemic control, with 8.7 percentage points more time spent in the target glucose range (70–180 mg/dL) compared to sensor augmented pump therapy (P<0.001). The closed loop system also reduced hyperglycemia and glycated hemoglobin levels without increasing hypoglycemia. The findings support the efficacy and safety of closed loop systems in this age group.